A meta-analysis of 2 trials of carotid endarterectomy (CEA) versus medical management for symptomatic carotid stenosis showed that time from the last symptomatic event to randomization significantly modified efficacy of surgery. 1 The benefits of endarterectomy were greatest for patients operated within 2 weeks after their last ischemic event. Emergent endarterectomy for stroke-in-evolution carries high operative risk, but for stable patients with minor stroke or transient ischemic attack (TIA), surgery in the first week after symptoms does not carry a substantially increased risk. 2 Early endarterectomy is thus often encouraged. 3 Some have suggested that stenting is safe even if done emergently in patients with symptomatic occlusion 4 ; however, small series suggest that early stenting carries greater risk than delayed stenting. 5 This analysis describes the relationship between time from symptoms to revascularization and periprocedural risk of stroke or death for both revascularization methods.
Methods
Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) randomized 2502 symptomatic and asymptomatic patients to either CEA or carotid artery stenting (CAS). The primary results have been published. 6 All governing review boards approved the protocol and every subject gave informed consent.
This analysis focuses on 1180 symptomatic patients receiving the assigned procedure within thirty days of randomization and in whom the timing of qualifying symptoms was documented. Time from qualifying symptoms to revascularization was treated as a categorical variable, with categories of <15, 15 to 60, and >60 days. The current analysis used the outcome of periprocedural stroke or death. The periprocedural period was defined as 30 days after procedure for those receiving treatment within 30 days of randomization or 36 days after randomization for those not receiving treatment within 30 days.
Results
The qualifying ischemic event was a transient ischemic attack for 42% (499/1180) of individuals, an ischemic stroke for Background and Purpose-Prior meta-analysis showed that carotid endarterectomy benefits decline with increasing surgical delay following symptoms. For symptomatic patients in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), we assessed if differences in time between symptoms and carotid endarterectomy or carotid artery stenting are associated with differences in risk of periprocedural stroke or death. Methods-We analyzed the 1180 symptomatic patients in CREST who received their assigned procedure and had clearly defined timing of symptoms. Patients were classified into 3 groups based on time from symptoms to procedure: <15, 15 to 60, and >60 days. Results-For carotid endarterectomy, risk of periprocedural stroke or death was not significantly different for the 2 later time periods relative to the earliest time period (hazard ratio, 0.74; 95% confidence interval, 0. Median time from symptoms to randomization was 15 days (interquartile range, 5-49) for CEA and 14 days (interquartile range, 5-44) for CAS. Median time from symptoms to revascularization was 22 days (interquartile range, 8-58) for CEA (n=597) and 18 days (interquartile range, 8-51) for CAS (n=583). Fifty-nine percent of patients had endarterectomy within 30 days; 60%, stenting within 30 days. Thirty-nine percent of patients had endarterectomy within 14 days; 43%, stenting within 14 days. A total of 3.2% of endarterectomies were performed within 2 days, and 5.3% of stenting cases were performed within 2 days. Timing of revascularization did not differ significantly by revascularization method (Table 1) .
Overall, the risk of a periprocedural stroke or death end point was 4.2% (50/1180). 
Discussion
Time from symptoms to treatment did not affect periprocedural safety of CEA or CAS or the risk of stroke after the periprocedural period. Early revascularization seems to be safe for both procedures.
Because patients were not randomized to early versus delayed surgery, it is not possible to conclude definitively that 
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timing of revascularization had no effect on risk. Unknown or unmeasured differences between early and later revascularized patients may have confounded the comparison of risks.
However, given the current recommendations to revascularize early, intentionally delaying treatment would not be ethical. Furthermore, by not having a treatment group managed purely medically, we cannot conclude that delayed surgery is appropriate simply because it seems to carry no greater risk of complications. Early treatment should be the goal because it ought to lead to less time at risk of artery-to-artery embolism. Timing should not be used to influence the decision to perform stenting versus endarterectomy in patients with symptomatic carotid stenosis.
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